WO2011000020A1 - Enhanced method of detection - Google Patents

Enhanced method of detection Download PDF

Info

Publication number
WO2011000020A1
WO2011000020A1 PCT/AU2009/001080 AU2009001080W WO2011000020A1 WO 2011000020 A1 WO2011000020 A1 WO 2011000020A1 AU 2009001080 W AU2009001080 W AU 2009001080W WO 2011000020 A1 WO2011000020 A1 WO 2011000020A1
Authority
WO
WIPO (PCT)
Prior art keywords
keratin
sample
condition
cancer
enhancer agent
Prior art date
Application number
PCT/AU2009/001080
Other languages
French (fr)
Inventor
Peter William French
Dharmica Mistry
Joseph Haklani
Original Assignee
Sbc Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009902727A external-priority patent/AU2009902727A0/en
Application filed by Sbc Research Pty Ltd filed Critical Sbc Research Pty Ltd
Publication of WO2011000020A1 publication Critical patent/WO2011000020A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/42—Arrangements for detecting radiation specially adapted for radiation diagnosis
    • A61B6/4208—Arrangements for detecting radiation specially adapted for radiation diagnosis characterised by using a particular type of detector
    • A61B6/4225—Arrangements for detecting radiation specially adapted for radiation diagnosis characterised by using a particular type of detector using image intensifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/40—Arrangements for generating radiation specially adapted for radiation diagnosis
    • A61B6/4064—Arrangements for generating radiation specially adapted for radiation diagnosis specially adapted for producing a particular type of beam
    • A61B6/4092—Arrangements for generating radiation specially adapted for radiation diagnosis specially adapted for producing a particular type of beam for producing synchrotron radiation

Definitions

  • the present invention relates to diagnostics and enhancing diagnostic tools and methods to identify one or more conditions in a subject.
  • Cancer and in particular breast cancer, is one example that clearly demonstrates excellent survival statistics when early-stage disease is treated using current therapies.
  • diagnosis is made too late. If all cases of breast cancer could be detected prior to metastasis then there would be a significant reduction of both individual mortality and the economic burden on the community.
  • One of the key imperatives in cancer research, including breast cancer research, therefore, is the need to develop more effective screening tools for the early detection of disease.
  • Biomarke.rs are biological molecules that are indicators of biological and pathological processes, or physiological and pharmacological responses to a drug treatment. Since biomarkers can be used to measure the progress of disease or the response to treatment, they have very significant potential roles to play in both the diagnosis and prognosis of disease. Ideally, in the case of breast cancer a biomarker signature would be able to detect cancer in asymptomatic patients and improve the accuracy of screening mammograms. A reliable biomarker signature may also signify new cancer,, even in the setting of normal physical examination results, and would indicate further more intensive diagnostic workup and/or preventive treatment.
  • SAXS small angle X-ray scattering
  • the SAXS patterns of hair from cancer patients contained a ring of comparatively low intensity which was superimposed on the normal ⁇ -keratin pattern obtained from healthy control subjects.
  • the nature of the ring seen on the X-ray diffraction (XRD) pattern to date has been unknown.
  • the present invention based on an understanding of the underlying molecular cause of the ring provides an improved method to identify conditions such as breast cancer. This understanding and the findings set out in this invention also allow identification of conditions other than breast cancer,
  • a method of enhancing an X-ray diffraction image of an abnormal keratin- containing sample obtained from a subject wherein the identification of an abnormal keratin-containing sample is indicative of one or more conditions said method including:
  • a method of identifying a condition which changes a lipid profile in a keratin- containing component of a subject including: obtaining a sample of said keratin-containing component from the subject;
  • the enhancer agent enhances a change present in the sample from a subject having said condition, said change resulting from a changed lipid profile in said keratin-containing component.
  • the condition includes any condition which results in an increase in lipid in keratin.
  • the condition may comprise a neoplastic condition.
  • the neoplastic condition may comprise a wide range of cancers and is not limited to a specific cancer, with the proviso that. said cancer alters the lipid profile of the keratin. Examples of cancers include cancer of the breast, colon, lung, cervix, pancreas, stomach, vagina, oesophagus, kidney, ovary, duodenum, small intestine, rectum, salivary gland, or cecum.
  • the condition may result in an alteration of the lipid profile in the keratin- containing component by a number of pathways.
  • the condition may cause an alteration in normal metabolic pathways of one or more lipid species.
  • the alteration in the keratin-containing component which may be detected by X- ' ray diffraction analysis may result from the incorporation or altered biosynthesis of one . or more of a large number of lipids in the sample taken from the subject.
  • Examples include, but are not limited to phospholipids including phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphocholine; sphingolipids including sphingomyelin, sphingosine; palmitic acid, palmitoleic acid, arachidonic acid; linoleic acid and choline.
  • phospholipids including phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphocholine
  • sphingolipids including sphingomyelin, sphingosine
  • palmitic acid palmitoleic acid, arachidonic acid
  • linoleic acid and choline examples include, but are not limited to phospholipids including phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphocholine
  • sphingolipids including sphingomyel
  • the condition may alter normal phospholipid metabolism or composition in body tissues and/or fluids.
  • various metabolites in the phospholipid metabolism, pathway may be altered.
  • the metabolic pathway of choline may be altered to ultimately cause an altered composition or biosynthesis of choline phospholipids in a keratin-containing component.
  • the condition may cause a change in the profile of a fatty acid containing compound such as sebum in a keratin-containing component of the subject.
  • a fatty acid containing compound such as sebum in a keratin-containing component of the subject.
  • the keratin-containing component of the present invention may include, but is not limited to any type of body hair, nail, skin and cuticle.
  • the keratin-containing sample may be taken from any of these components. .
  • the enhancer agent may be any agent which reacts with lipids.
  • the ieaction with the lipid provides an enhanced X ray diffraction pattern of the lipid feature.
  • the enhancer agent may react with specific groups on lipids.
  • the enhancer agent may react with phosphate groups on certain lipids.
  • the enhancer agent may include an imidazole group which reacts with the phosphate group on the phospholipids.
  • the enhancer agent preferably includes a metal group.
  • the metal group preferably has a high electronic density to generate a strong X-ray diffraction signal.
  • enhancer agents include alkaline salts.
  • the enhancer agent may be lead nitrate or lead acetate.
  • a method for enhancing an X-ray diffraction image of an abnormal keratin-containing sample obtained from a subject wherein the identification of an abnormal keratin-containing• sample is indicative of one or more conditions said method including:
  • the X-ray diffraction pattern of the keratin-containing material includes a ring at a certain spacing from the centre of the pattern.
  • the enhancer agent of the present invention intensifies the X-ray diffraction of this ring such that the ring is more prevalent when analysed.
  • a particularly weak signal for example in instances where the lipid profile may have been only changed slightly will more likely be noted upon analysis due to enhancement by the enhancer agent.
  • the enhanced ring of the present invention may be observed at a molecular spacing of 4.76 ⁇ 0.07 nm. (Corino G & French P, M J Cancer 122: 847-856, 2008)
  • the use of a specific enhancer that reacts with lipid may provide a means to enhance the altered aspect of the X-ray diffraction pattern of the keratin-containing sample.
  • Figure 1 shows A) a normal X-ray diffraction pattern of hair and B) an abnormal X-ray diffraction pattern of hair;
  • Figure 2 shows A) an X-ray diffraction pattern of a hair with no ring and B) the X-ray diffraction pattern following soaking of the hair of A) in olive oil;
  • Figure 3 shows the effect of solvent on the X-ray diffraction pattern of a hair exhibiting a ring
  • Figure 4 shows enhancement of a ring observed from the results of X-ray diffraction by using lead nitrate.
  • the X-rays used are derived from synchrotron radiation or other monochromatic X-ray sources providing X-rays within the energy range of five to twenty-five keV.
  • the keratin-containing component studied was hair
  • a single hair was used.
  • the hair was mounted on a holder under sufficient " tension to maintain alignment.
  • the holder was mounted on a motorised translation device capable of moving in l ⁇ m steps in the vertical and horizontal planes which enabled each sample to be precisely located in the X-ray beam.
  • the hair fibres were mounted "with the axis of the hair in the parallel plane and at a 90 degree angle of incidence to the X-ray source.
  • the wavelength of the X-ray beam was approximately 1.1 A and had a resolution ( ⁇ E/E) of l ⁇ l 0 "4 .
  • each fibre was exposed to the X-ray source for a set period of time depending on the intensity of the beam. In general each sample was exposed to a total of approximately IxIO 14 photons. The resultant diffraction patterns were collected on a MARl 65 CCD detector. Sample to detector distance was approximately 600 mm.
  • a sample of hair from a breast cancer patient (as shown in Fig IB) is lipid-derived.
  • the present invention addresses this by the finding that the ring is due to the presence of additional lipids incorporated into the structure of keratin- containing components.
  • FIG. 2A A sample of hair which did not have a ring (this .was confirmed by X-ray diffraction) was selected.
  • the diffraction pattern of this hair is shown in Figure 2A.
  • the hair was then soaked in olive oil for 10 minutes, wiped dry and then re- exposed to X-rays.
  • the resulting diffraction pattern is depicted in Figure 2B wherein a clear ring is visible.
  • the ring resulting from soaking in olive oil is very similar in appearance and d-spacing to the ring shown in Figure IB from a breast cancer patient.
  • chloroform/methanol hi this ratio is used to extract neutral lipids, diacylglcerophosphol ⁇ pids and most sphingolipids from biological material with low lipid content.
  • X-ray diffraction to establish the presence of an abnormality, in the form of a ring or halo, suggests that a patient from whom the sample is taken suffers from a condition which affects a keratin-containing component such as a hair.
  • the present inventors have found that the associated ring in the pattern is due to a change in the lipid content of the keratin-containing component.
  • the inventors have found a method of enhancing an abnormal pattern to thereby provide a reliable diagnostic tool in the early detection of conditions including breast cancer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)

Abstract

A method of enhancing an X-ray diffraction image of an abnormal keratin-containing sample obtained from a subject by applying an enhancer agent to the keratin containing sample and then subjecting the sample to X-rays to obtain an X-ray diffraction image. The enhancer agent enhances a change present in an abnormal keratin-containing sample, said change having been caused by a particular condition of the subject condition.

Description

"Enhanced Method of Detection"
Cross-Reference to Related Applications The present application claims priority from Australian: Provisional Patent
Application No 2009902727 filed on 12 June 2009, the content of which is incorporated herein by reference.
Field of the Invention
The present invention relates to diagnostics and enhancing diagnostic tools and methods to identify one or more conditions in a subject.
Background Art
Methods for early stage detection of disease in order to maximize treatment outcomes are clearly desirable. Cancer, and in particular breast cancer, is one example that clearly demonstrates excellent survival statistics when early-stage disease is treated using current therapies. However, for many patients diagnosis is made too late. If all cases of breast cancer could be detected prior to metastasis then there would be a significant reduction of both individual mortality and the economic burden on the community. One of the key imperatives in cancer research, including breast cancer research, therefore, is the need to develop more effective screening tools for the early detection of disease.
Biomarke.rs are biological molecules that are indicators of biological and pathological processes, or physiological and pharmacological responses to a drug treatment. Since biomarkers can be used to measure the progress of disease or the response to treatment, they have very significant potential roles to play in both the diagnosis and prognosis of disease. Ideally, in the case of breast cancer a biomarker signature would be able to detect cancer in asymptomatic patients and improve the accuracy of screening mammograms. A reliable biomarker signature may also signify new cancer,, even in the setting of normal physical examination results, and would indicate further more intensive diagnostic workup and/or preventive treatment.
■ . Reported differences in the small angle X-ray scattering (SAXS) patterns of hair from individuals with breast cancer compared to healthy subjects has been reported and is the subject of WO 00/34774, the contents of which are herein incorporated by reference.
■
The SAXS patterns of hair from cancer patients contained a ring of comparatively low intensity which was superimposed on the normal α-keratin pattern obtained from healthy control subjects. The nature of the ring seen on the X-ray diffraction (XRD) pattern to date has been unknown.
The present invention, based on an understanding of the underlying molecular cause of the ring provides an improved method to identify conditions such as breast cancer. This understanding and the findings set out in this invention also allow identification of conditions other than breast cancer,
Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.
Summary of the Invention A method of enhancing an X-ray diffraction image of an abnormal keratin- containing sample obtained from a subject wherein the identification of an abnormal keratin-containing sample is indicative of one or more conditions, said method including:
obtaining a keratin-containing sample from the subject;
applying an enhancer agent to said sample;
subjecting the sample to X-rays to obtain said X-ray diffraction image;
wherein -the enhancer agent enhances a change present in an abnormal keratin- containing sample, said change having been caused by said condition. A method of identifying a condition which changes a lipid profile in a keratin- containing component of a subject, said method including: obtaining a sample of said keratin-containing component from the subject;
applying an enhancer agent to said sample;
subjecting the sample to X-rays to obtain said X-ray diffraction image;
wherein the enhancer agent enhances a change present in the sample from a subject having said condition, said change resulting from a changed lipid profile in said keratin-containing component.
The method of either of the above aspects wherein said condition includes any condition which results in an increase in lipid in keratin. The condition may comprise a neoplastic condition. The neoplastic condition may comprise a wide range of cancers and is not limited to a specific cancer, with the proviso that. said cancer alters the lipid profile of the keratin. Examples of cancers include cancer of the breast, colon, lung, cervix, pancreas, stomach, vagina, oesophagus, kidney, ovary, duodenum, small intestine, rectum, salivary gland, or cecum.
The condition may result in an alteration of the lipid profile in the keratin- containing component by a number of pathways. The condition may cause an alteration in normal metabolic pathways of one or more lipid species. The alteration in the keratin-containing component which may be detected by X- ' ray diffraction analysis may result from the incorporation or altered biosynthesis of one . or more of a large number of lipids in the sample taken from the subject. Examples include, but are not limited to phospholipids including phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphocholine; sphingolipids including sphingomyelin, sphingosine; palmitic acid, palmitoleic acid, arachidonic acid; linoleic acid and choline.
In one embodiment, the condition may alter normal phospholipid metabolism or composition in body tissues and/or fluids. In this embodiment, various metabolites in the phospholipid metabolism, pathway may be altered. As an example, the metabolic pathway of choline may be altered to ultimately cause an altered composition or biosynthesis of choline phospholipids in a keratin-containing component.
In a further embodiment, the condition may cause a change in the profile of a fatty acid containing compound such as sebum in a keratin-containing component of the subject. The keratin-containing component of the present invention may include, but is not limited to any type of body hair, nail, skin and cuticle. The keratin-containing sample may be taken from any of these components..
The enhancer agent may be any agent which reacts with lipids. The ieaction with the lipid provides an enhanced X ray diffraction pattern of the lipid feature.
The enhancer agent may react with specific groups on lipids. For example, the enhancer agent may react with phosphate groups on certain lipids. Further, the enhancer agent may include an imidazole group which reacts with the phosphate group on the phospholipids. In a. further embodiment, the enhancer agent preferably includes a metal group. The metal group preferably has a high electronic density to generate a strong X-ray diffraction signal. Further examples of enhancer agents include alkaline salts. Still further, the enhancer agent may be lead nitrate or lead acetate.
According to another aspect of the present invention, there is provided a method for enhancing an X-ray diffraction image of an abnormal keratin-containing sample obtained from a subject wherein the identification of an abnormal keratin-containing• sample is indicative of one or more conditions, said method including:
subjecting the keratin-containing sample to an enhancer agent;
providing an X-ray source producing a beam of X-ray radiation;
positioning said keratin-containing sample on a sample stage within said beam; . detecting the scattering of said X-ray beam caused by said keratin-containing sample; and
displaying the output;
whereby a pattern of output indicative of an abnormal keratin-containing sample is enhanced by said enhancer agent. In one embodiment of any of the above aspects, the X-ray diffraction pattern of the keratin-containing material includes a ring at a certain spacing from the centre of the pattern. The enhancer agent of the present invention intensifies the X-ray diffraction of this ring such that the ring is more prevalent when analysed. A particularly weak signal, for example in instances where the lipid profile may have been only changed slightly will more likely be noted upon analysis due to enhancement by the enhancer agent. In the embodiment wherein the condition comprises breast cancer, the enhanced ring of the present invention may be observed at a molecular spacing of 4.76 ± 0.07 nm. (Corino G & French P, M J Cancer 122: 847-856, 2008)
If the lipid profile of. a keratin-containing sample is altered due to a subject suffering from a condition which alters this lipid profile, the use of a specific enhancer that reacts with lipid may provide a means to enhance the altered aspect of the X-ray diffraction pattern of the keratin-containing sample.
Brief Description of the Drawings
Figure 1 shows A) a normal X-ray diffraction pattern of hair and B) an abnormal X-ray diffraction pattern of hair;
Figure 2 shows A) an X-ray diffraction pattern of a hair with no ring and B) the X-ray diffraction pattern following soaking of the hair of A) in olive oil;
Figure 3 shows the effect of solvent on the X-ray diffraction pattern of a hair exhibiting a ring;
Figure 4 shows enhancement of a ring observed from the results of X-ray diffraction by using lead nitrate. Description of an Exemplary Embodiment of the Invention Examples
In the following described experimentation, the X-rays used are derived from synchrotron radiation or other monochromatic X-ray sources providing X-rays within the energy range of five to twenty-five keV.
Where the keratin-containing component studied was hair, a single hair was used. The hair was mounted on a holder under sufficient" tension to maintain alignment. The holder was mounted on a motorised translation device capable of moving in lμm steps in the vertical and horizontal planes which enabled each sample to be precisely located in the X-ray beam. The hair fibres were mounted "with the axis of the hair in the parallel plane and at a 90 degree angle of incidence to the X-ray source. The wavelength of the X-ray beam was approximately 1.1 A and had a resolution (ΔE/E) of lχl 0"4.
Each fibre was exposed to the X-ray source for a set period of time depending on the intensity of the beam. In general each sample was exposed to a total of approximately IxIO14 photons. The resultant diffraction patterns were collected on a MARl 65 CCD detector. Sample to detector distance was approximately 600 mm.
.
Experiments
To determine that the ring found in a sample of hair from a breast cancer patient (as shown in Fig IB) is lipid-derived.
From the applicant's previous studies, it is evident that certain conditions such as breast cancer, colon cancer and Alzheimer's disease result in the alteration of a keratin- containing component such as hair. This alteration may be detected using the X-ray diffraction technique outlined above. In patients suffering from breast cancer, a ring is observed. The diffraction pattern from a sample of hair from a healthy person is shown in Fig. IA and that from a breast cancer patient shown in Figure IB. The ring reported to be associated with the presence of breast cancer can be seen in the diffraction pattern in Fig IB. To date, it has been unclear what causes this ring to appear. It has been speculated that it is due to an 'additional component' secreted from the breast cancer and taken up by the hair. The present invention addresses this by the finding that the ring is due to the presence of additional lipids incorporated into the structure of keratin- containing components.
Experiment 1
Addition of fatty acids to hair
A sample of hair which did not have a ring (this .was confirmed by X-ray diffraction) was selected. The diffraction pattern of this hair is shown in Figure 2A. The hair was then soaked in olive oil for 10 minutes, wiped dry and then re- exposed to X-rays. The resulting diffraction pattern is depicted in Figure 2B wherein a clear ring is visible. The ring resulting from soaking in olive oil is very similar in appearance and d-spacing to the ring shown in Figure IB from a breast cancer patient.
Experiment 2
Solvent extraction of hairs Hairs from breast cancer patients which displayed rings were run on a synchrotron SAXS beamline (Australian Synchrotron) to confirm the presence of the ring. The individual hairs were then soaked in a solvent for 2 hours, rinsed in MiIIiQ water, dried and then re-run very close to the same point on the hair fibre. The solvents used were:
A Isopropanol (100%)
B Chloroform (100%)
C Chloroform/methanol (1:1)
D Chloroform/methanol (1:2)
The results are shown in Fig 3.
* While all solvents reduced the intensity of the ring in most fibres, it was evident that consistently, isopropanol was the least effective and chloroform/methanol (1:2)- was the most effective. This provided data to point to the species of lipid involved.
Particularly, chloroform/methanol hi this ratio is used to extract neutral lipids, diacylglcerophospholϊpids and most sphingolipids from biological material with low lipid content.
Experiment 3
Enhancement of the Lipid Ring using Lead Salts Hairs were soaked in 0.1 mol/1 lead nitrate, at pH 5.8, at room temperature for 2 hours. Hairs were thoroughly washed in three successive 5 min immersions in MiIIiQ water, using the method of Bertrand et aϊ (Bertrand L, Doucet J3 Simionovici A, Tsoucaris G, Walter P3 2003. Lead revealed lipid organization in human hair BBA 1620: 218-224.). The results showed that the breast cancer ring was significantly enhanced in most cases. Figure 4 shows the diffraction pattern of a sample hair before and after lipid enhancement by lead nitrate. The ring after enhancement is much stronger than that before exposure to the lead nitrate.
The use of X-ray diffraction to establish the presence of an abnormality, in the form of a ring or halo, suggests that a patient from whom the sample is taken suffers from a condition which affects a keratin-containing component such as a hair. The present inventors have found that the associated ring in the pattern is due to a change in the lipid content of the keratin-containing component.
With this understanding, the inventors have found a method of enhancing an abnormal pattern to thereby provide a reliable diagnostic tool in the early detection of conditions including breast cancer.
Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the scope of the invention as broadly described.
The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

Claims

CLAIMS:
1. A method of enhancing an X-ray diffraction image of an abnormal keratin- containing sample obtained from a subject wherein the identification of an abnormal keratin-contaming sample is indicative of one or more, conditions, said method including:
obtaining a keratin-containing sample from the subject;
applying an enhancer agent to said sample;
subjecting the sample to X-rays to obtain said X-ray diffraction image;
wherein the enhancer agent enhances a change present in an abnormal keratin- containing sample, said change having been caused by said condition.
2. The method of claim 1 wherein said condition includes any condition which alters the lipid profile of keratin of a subj ect.
3. The method of claim 1 wherein said condition includes any condition which results in an increase in lipid in keratin.
4. The method of any one of claims 1 to 3 wherein the condition to be detected includes a neoplastic condition.
5. The method of claim 4 wherein the neoplastic condition is breast cancer.
6. The method of claim 4 wherein the neoplastic condition is colon cancer.
7. The method of claim 4 wherein the neoplastic condition is lung cancer.
8. The method of claim 4 wherein the neoplastic condition is cervical cancer.
9. The method of claim 4 wherein the neoplastic condition is pancreatic cancer.
10. The method of claim 4 wherein the neoplastic condition is stomach cancer.
11. The method of claim 4 wherein the neoplastic condition is cancer of the vagina.
12. The method of claim 4 wherein the neoplastic condition is oesophageal cancer.
13. The method of claim 4 wherein the neoplastic condition is renal cancer.
5 14. The method of claim 4 wherein the neoplastic condition is ovarian cancer.
15. The method of claim 4 wherein the neoplastic condition is. cancer of the duodenum, small intestine, rectum or cecum.
10 16. The method of claim 4 wherein the neoplastic condition is cancer of the salivary glands.
17. The method of any one of the preceding claims wherein the keratin-containing component is hair.
15
18. The method of any one of claims 1 to 16 wherein the keratin-containing component is nail.
19. The method of any one of claims 1 to 16 wherein the keratin-containing 0 component is skin.
20. The method of any one of claims 1 to 16 wherein the keratin-containing component is cuticle. 5
21. The method of any one of the preceding claims, wherein the enhancer agent reacts with lipids.
22. The method of any one of the preceding claims wherein the. enhancer agent reacts with phosphate groups on a lipid.
0
23. The method of any one of the preceding claims wherein the enhancer agent includes an imidazole group.
24. The method of any one of the. preceding claims wherein the enhancer agent 5 includes a metal group. I l
25. The method of any one of claims 1 to 21 wherein the enhancer agent is an alkaline salt.
26. The method of any one of claims 1 to 21 wherein the enhancer agent is lead 5 nitrate.
27. The method of any one of claims 1 to 21 wherein the enhancer agent is lead acetate.
10 28. A method of identifying a condition which changes a lipid profile in a keratin- containing component of a subject, said method including:
obtaining a sample of said keratin-containing component from the subject; applying an enhancer agent to said sample;
subjecting the sample to X-rays to obtain said X-ray diffraction image; 15 wherein the enhancer agent enhances a change present in the sample from a subject having said condition, said change resulting from a changed lipid profile in said keratin-containing component.
,
29. A method for enhancing an X-ray diffraction image of an abnormal keratin- 0 containing sample obtained from a subject wherein the identification of an abnormal keratin-containing sample is indicative of one or more conditions, said method including:
subjecting the keratin-containing sample to an enhancer agent;
providing an X-ray source producing a beam of X-ray radiation;
5 positioning said keratin-containing sample on a sample stage within said beam;
detecting the scattering of said X-ray beam caused by said keratm-containirig sample; and
displaying the output;
whereby a pattern of output indicative of an abnormal keratin-containing sample is 0 enhanced by said enhancer agent.
30. The method of claim 29 wherein the X-ray diffraction pattern of the keratin- containing material includes a ring spaced from the centre of the pattern and wherein the enhancer agent intensifies the X-ray diffraction of said ring.
5
31. The method of claim 29 or claim 30 wherein the condition comprises breast cancer and the enhanced ring is observed at a molecular spacing of 4.76 ± 0.07 nm.
PCT/AU2009/001080 2009-06-12 2009-08-24 Enhanced method of detection WO2011000020A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2009902727A AU2009902727A0 (en) 2009-06-12 Enhanced Method of Detection
AU2009902727 2009-06-12

Publications (1)

Publication Number Publication Date
WO2011000020A1 true WO2011000020A1 (en) 2011-01-06

Family

ID=43410345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2009/001080 WO2011000020A1 (en) 2009-06-12 2009-08-24 Enhanced method of detection

Country Status (1)

Country Link
WO (1) WO2011000020A1 (en)

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049893A1 (en) * 2011-10-07 2013-04-11 Paul Chapman Animal enclosure
US20130110666A1 (en) * 2011-10-28 2013-05-02 Adidas Ag Interactive retail system
US8436896B2 (en) 2011-07-26 2013-05-07 ByteLight, Inc. Method and system for demodulating a digital pulse recognition signal in a light based positioning system using a Fourier transform
US8436363B2 (en) 2011-02-03 2013-05-07 Soitec Metallic carrier for layer transfer and methods for forming the same
US8437763B2 (en) 2009-10-23 2013-05-07 Intel Corporation Mechanisms to update a serving base station with the CSG memberships of a mobile station
US8435209B2 (en) 2009-12-30 2013-05-07 Medtronic Minimed, Inc. Connection and alignment detection systems and methods
US8435924B2 (en) 2009-11-04 2013-05-07 The Procter & Gamble Company Method of producing color change in overlapping layers
US8436404B2 (en) 2009-12-30 2013-05-07 Intel Corporation Self-aligned contacts
US8434575B2 (en) 2010-04-06 2013-05-07 Robotex Inc. Robotic system and methods of use
US8436135B2 (en) * 2006-12-20 2013-05-07 Brahms Gmbh Diagnosis and risk stratification by determining the marker CT-proADM
US8437285B2 (en) 2011-08-16 2013-05-07 Renesas Mobil Corporation Wireless device and base stations and methods of operating
US8437543B2 (en) 2010-09-16 2013-05-07 Thomson Licensing Method and device of determining a saliency map for an image
US8435615B2 (en) 2009-04-15 2013-05-07 Jsp Corporation Hollow foamed blow-molded article
US8435223B2 (en) 2009-01-15 2013-05-07 The Procter & Gamble Company Reusable outer cover for an absorbent article having zones of varying properties
US8438654B1 (en) 2012-09-14 2013-05-07 Rightscale, Inc. Systems and methods for associating a virtual machine with an access control right
US8435267B2 (en) 2006-04-24 2013-05-07 Spinefrontier Inc Spine fixation method and apparatus
US8436012B2 (en) 2008-08-05 2013-05-07 Daiichi Sankyo Company, Limited Imidazopyridin-2-one derivatives
US8435454B2 (en) 2009-07-09 2013-05-07 Siemens Medical Solutions Usa, Inc. Modular system for radiosynthesis with multi-run capabilities and reduced risk of radiation exposure
US8437302B2 (en) 2011-08-12 2013-05-07 Renesas Mobile Corporation Method and apparatus for transmission protocol uplink channel selection
US8435777B1 (en) 2012-01-20 2013-05-07 Cayla CPG-free gene for a new secreted reporter protein
US8435552B2 (en) 2007-02-09 2013-05-07 Royal College Of Surgeons In Ireland Collagen/hydroxyapatite composite scaffold, and process for the production thereof
US8436001B2 (en) 2010-04-07 2013-05-07 F. Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
US8435728B2 (en) 2010-03-31 2013-05-07 Tokyo Electron Limited Method of slimming radiation-sensitive material lines in lithographic applications
US8435999B2 (en) 2007-08-13 2013-05-07 Monsanto Technology Llc Compositions and methods for controlling nematodes
US8436436B2 (en) 2006-08-01 2013-05-07 Washington University Multifunctional nanoscopy for imaging cells
US8435523B2 (en) 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
US8435988B2 (en) 2010-10-06 2013-05-07 Glaxosmithkline Llc Benzimidazole derivatives as P13 kinase inhibitors
US8435727B2 (en) 2010-10-01 2013-05-07 Varian Semiconductor Equipment Associates, Inc. Method and system for modifying photoresist using electromagnetic radiation and ion implantation
US8438595B1 (en) 2011-11-04 2013-05-07 General Instrument Corporation Method and apparatus for temporal correlation of content-specific metadata with content obtained from disparate sources
US8436073B2 (en) 2009-10-06 2013-05-07 Amcol International Lignite-based foundry resins
US8435754B2 (en) * 2005-12-19 2013-05-07 Genetech, Inc. Method of diagnosing the presence of a tumor in a mammal by assessing CDO expression levels
US8435902B2 (en) 2010-03-17 2013-05-07 Applied Materials, Inc. Invertable pattern loading with dry etch
US8436015B2 (en) 2008-09-15 2013-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8436175B2 (en) 2010-03-22 2013-05-07 Rensselaer Polytechnic Institute Carboxamide bioisosteres of opiates
US8435998B2 (en) 2008-07-03 2013-05-07 Sandoz Ag Crystalline form of posaconazole
US8435789B2 (en) 2010-02-15 2013-05-07 Provitro Biosciences Llc Media, kits, systems and methods for the micropropagation of bamboo
US8434378B2 (en) 2010-04-12 2013-05-07 Distek, Inc. Dissolution-testing vessel cover
US8437882B2 (en) 2010-02-17 2013-05-07 Inscope Energy, Llc Managing power utilized within a local power network
US8437268B2 (en) 2010-02-12 2013-05-07 Research In Motion Limited System and method for intra-cell frequency reuse in a relay network
US8435765B2 (en) 2002-04-23 2013-05-07 Cargill, Incorporated Polypeptides and biosynthetic pathways for the production of monatin and its precursors
US8435809B2 (en) 2009-09-25 2013-05-07 Intel Corporation Vertical mirror in a silicon photonic circuit
US8437082B2 (en) 2011-02-11 2013-05-07 AMI Resaerch & Development, LLC Orthogonal scattering features for solar array
WO2013128429A1 (en) 2012-03-02 2013-09-06 Econation Light monitoring system and method for operating the light monitoring system
WO2013132414A1 (en) 2012-03-09 2013-09-12 Sensile Pat Ag Drug reconstitution system
WO2013132448A1 (en) 2012-03-07 2013-09-12 Kba-Notasys Sa Method of checking producibility of a composite security design of a security document on a line of production equipment and digital computer environment for implementing the same
WO2013132381A1 (en) 2012-03-06 2013-09-12 Koninklijke Philips N.V. Light emitting arrangement
WO2013132405A1 (en) 2012-03-07 2013-09-12 L'oreal Packaging and application device
WO2013140219A1 (en) 2012-03-19 2013-09-26 Bertelli & Partners S.R.L. Improved method for electronically regulating a combustible mixture, for example gas fed to a burner
WO2013140281A1 (en) 2012-03-19 2013-09-26 Gea Mechanical Equipment Italia S.P.A. Apparatus for thermal treatment of water with regeneration for flushing aseptic chambers of high-pressure homogenisers or pumps
WO2013150280A2 (en) 2012-04-03 2013-10-10 Cff Technologies Limited Downhole actuator
WO2013153400A2 (en) 2012-04-12 2013-10-17 Cambridge Mechatronics Limited Sma actuation apparatus
EP2657132A2 (en) 2012-04-25 2013-10-30 Airbus Operations GmbH Passenger service system with improved air guidance
EP2657329A1 (en) 2012-04-26 2013-10-30 Viking Temizlik Ve Kozmetik Ürünleri Pazarlama Sanayi Ticaret Anomim Sirketi Sequestering agent used in detergents with high calcium binding capacity
WO2013160221A1 (en) 2012-04-25 2013-10-31 Hettich-Oni Gmbh & Co. Kg Sliding door fitting
WO2013160236A1 (en) 2012-04-24 2013-10-31 Saint-Gobain Ceramic Materials A. S. Silicon nitride containing crucible and a method of producing the silicon nitride containing crucible
EP2661028A1 (en) 2012-04-30 2013-11-06 Fujitsu Limited Duplicate Packet Suppression
WO2013164213A1 (en) 2012-05-04 2013-11-07 Construction Research & Technology Gmbh Process for manufacturing a hydraulic bonding agent, corresponding additive and its use
WO2013171027A1 (en) 2012-05-16 2013-11-21 Unilever N.V. Process for the preparation of edible fat-continuous emulsions
EP2792388A1 (en) 2013-04-19 2014-10-22 Scientific RT GmbH Operating method for an irradiation device
EP2796818A1 (en) 2013-04-22 2014-10-29 Shell Internationale Research Maatschappij B.V. Method and apparatus for producing a liquefied hydrocarbon stream
EP2797200A1 (en) 2013-04-22 2014-10-29 Sanofi-Aventis Deutschland GmbH Apparatus with removable battery
EP2796158A1 (en) 2013-04-22 2014-10-29 Sanofi-Aventis Deutschland GmbH Apparatus including light sources
WO2014173434A1 (en) 2013-04-22 2014-10-30 Sanofi-Aventis Deutschland Gmbh Supplemental device for attachment to an injection device
AT520381A1 (en) * 2017-09-13 2019-03-15 Anton Paar Gmbh X-ray device and method for small angle scattering
WO2019186577A1 (en) 2018-03-27 2019-10-03 Council Of Scientific And Industrial Research A non-invasive and remote method to screen cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034774A1 (en) * 1998-12-10 2000-06-15 Fiberscan Pty Ltd Using hair to screen for breast cancer
WO2003060513A2 (en) * 2002-01-04 2003-07-24 E2V Technologies Limited Method and apparatus for cancer detection
WO2008000020A1 (en) * 2006-06-29 2008-01-03 Fermiscan Australia Pty Limited Improved process
WO2008083430A1 (en) * 2007-01-12 2008-07-17 Veronica James Biometric diagnosis
WO2008134800A1 (en) * 2007-05-04 2008-11-13 Fermiscan Australia Pty Limited Sample analysis system
WO2009043115A1 (en) * 2007-10-04 2009-04-09 Fermiscan Australia Pty Limited Method for identifying biomarkers which are diagnostic for a pathological condition

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034774A1 (en) * 1998-12-10 2000-06-15 Fiberscan Pty Ltd Using hair to screen for breast cancer
WO2003060513A2 (en) * 2002-01-04 2003-07-24 E2V Technologies Limited Method and apparatus for cancer detection
WO2008000020A1 (en) * 2006-06-29 2008-01-03 Fermiscan Australia Pty Limited Improved process
WO2008083430A1 (en) * 2007-01-12 2008-07-17 Veronica James Biometric diagnosis
WO2008134800A1 (en) * 2007-05-04 2008-11-13 Fermiscan Australia Pty Limited Sample analysis system
WO2009043115A1 (en) * 2007-10-04 2009-04-09 Fermiscan Australia Pty Limited Method for identifying biomarkers which are diagnostic for a pathological condition

Cited By (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435765B2 (en) 2002-04-23 2013-05-07 Cargill, Incorporated Polypeptides and biosynthetic pathways for the production of monatin and its precursors
US8435754B2 (en) * 2005-12-19 2013-05-07 Genetech, Inc. Method of diagnosing the presence of a tumor in a mammal by assessing CDO expression levels
US8435267B2 (en) 2006-04-24 2013-05-07 Spinefrontier Inc Spine fixation method and apparatus
US8436436B2 (en) 2006-08-01 2013-05-07 Washington University Multifunctional nanoscopy for imaging cells
US8436135B2 (en) * 2006-12-20 2013-05-07 Brahms Gmbh Diagnosis and risk stratification by determining the marker CT-proADM
US8435552B2 (en) 2007-02-09 2013-05-07 Royal College Of Surgeons In Ireland Collagen/hydroxyapatite composite scaffold, and process for the production thereof
US8435999B2 (en) 2007-08-13 2013-05-07 Monsanto Technology Llc Compositions and methods for controlling nematodes
US8435998B2 (en) 2008-07-03 2013-05-07 Sandoz Ag Crystalline form of posaconazole
US8436012B2 (en) 2008-08-05 2013-05-07 Daiichi Sankyo Company, Limited Imidazopyridin-2-one derivatives
US8436015B2 (en) 2008-09-15 2013-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8435223B2 (en) 2009-01-15 2013-05-07 The Procter & Gamble Company Reusable outer cover for an absorbent article having zones of varying properties
US8435615B2 (en) 2009-04-15 2013-05-07 Jsp Corporation Hollow foamed blow-molded article
US8435523B2 (en) 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
US8435454B2 (en) 2009-07-09 2013-05-07 Siemens Medical Solutions Usa, Inc. Modular system for radiosynthesis with multi-run capabilities and reduced risk of radiation exposure
US8435809B2 (en) 2009-09-25 2013-05-07 Intel Corporation Vertical mirror in a silicon photonic circuit
US8436073B2 (en) 2009-10-06 2013-05-07 Amcol International Lignite-based foundry resins
US8437763B2 (en) 2009-10-23 2013-05-07 Intel Corporation Mechanisms to update a serving base station with the CSG memberships of a mobile station
US8435924B2 (en) 2009-11-04 2013-05-07 The Procter & Gamble Company Method of producing color change in overlapping layers
US8436404B2 (en) 2009-12-30 2013-05-07 Intel Corporation Self-aligned contacts
US8435209B2 (en) 2009-12-30 2013-05-07 Medtronic Minimed, Inc. Connection and alignment detection systems and methods
US8437268B2 (en) 2010-02-12 2013-05-07 Research In Motion Limited System and method for intra-cell frequency reuse in a relay network
US8435789B2 (en) 2010-02-15 2013-05-07 Provitro Biosciences Llc Media, kits, systems and methods for the micropropagation of bamboo
US8437882B2 (en) 2010-02-17 2013-05-07 Inscope Energy, Llc Managing power utilized within a local power network
US8435902B2 (en) 2010-03-17 2013-05-07 Applied Materials, Inc. Invertable pattern loading with dry etch
US8436175B2 (en) 2010-03-22 2013-05-07 Rensselaer Polytechnic Institute Carboxamide bioisosteres of opiates
US8435728B2 (en) 2010-03-31 2013-05-07 Tokyo Electron Limited Method of slimming radiation-sensitive material lines in lithographic applications
US8434575B2 (en) 2010-04-06 2013-05-07 Robotex Inc. Robotic system and methods of use
US8436001B2 (en) 2010-04-07 2013-05-07 F. Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
US8434378B2 (en) 2010-04-12 2013-05-07 Distek, Inc. Dissolution-testing vessel cover
US8437543B2 (en) 2010-09-16 2013-05-07 Thomson Licensing Method and device of determining a saliency map for an image
US8435727B2 (en) 2010-10-01 2013-05-07 Varian Semiconductor Equipment Associates, Inc. Method and system for modifying photoresist using electromagnetic radiation and ion implantation
US8435988B2 (en) 2010-10-06 2013-05-07 Glaxosmithkline Llc Benzimidazole derivatives as P13 kinase inhibitors
US8436363B2 (en) 2011-02-03 2013-05-07 Soitec Metallic carrier for layer transfer and methods for forming the same
US8437082B2 (en) 2011-02-11 2013-05-07 AMI Resaerch & Development, LLC Orthogonal scattering features for solar array
US8436896B2 (en) 2011-07-26 2013-05-07 ByteLight, Inc. Method and system for demodulating a digital pulse recognition signal in a light based positioning system using a Fourier transform
US8437302B2 (en) 2011-08-12 2013-05-07 Renesas Mobile Corporation Method and apparatus for transmission protocol uplink channel selection
US8437285B2 (en) 2011-08-16 2013-05-07 Renesas Mobil Corporation Wireless device and base stations and methods of operating
WO2013049893A1 (en) * 2011-10-07 2013-04-11 Paul Chapman Animal enclosure
US20130110666A1 (en) * 2011-10-28 2013-05-02 Adidas Ag Interactive retail system
US8438595B1 (en) 2011-11-04 2013-05-07 General Instrument Corporation Method and apparatus for temporal correlation of content-specific metadata with content obtained from disparate sources
US8435777B1 (en) 2012-01-20 2013-05-07 Cayla CPG-free gene for a new secreted reporter protein
WO2013128429A1 (en) 2012-03-02 2013-09-06 Econation Light monitoring system and method for operating the light monitoring system
WO2013132381A1 (en) 2012-03-06 2013-09-12 Koninklijke Philips N.V. Light emitting arrangement
WO2013132448A1 (en) 2012-03-07 2013-09-12 Kba-Notasys Sa Method of checking producibility of a composite security design of a security document on a line of production equipment and digital computer environment for implementing the same
WO2013132405A1 (en) 2012-03-07 2013-09-12 L'oreal Packaging and application device
WO2013132414A1 (en) 2012-03-09 2013-09-12 Sensile Pat Ag Drug reconstitution system
WO2013140219A1 (en) 2012-03-19 2013-09-26 Bertelli & Partners S.R.L. Improved method for electronically regulating a combustible mixture, for example gas fed to a burner
WO2013140281A1 (en) 2012-03-19 2013-09-26 Gea Mechanical Equipment Italia S.P.A. Apparatus for thermal treatment of water with regeneration for flushing aseptic chambers of high-pressure homogenisers or pumps
WO2013150280A2 (en) 2012-04-03 2013-10-10 Cff Technologies Limited Downhole actuator
WO2013153400A2 (en) 2012-04-12 2013-10-17 Cambridge Mechatronics Limited Sma actuation apparatus
WO2013160236A1 (en) 2012-04-24 2013-10-31 Saint-Gobain Ceramic Materials A. S. Silicon nitride containing crucible and a method of producing the silicon nitride containing crucible
EP2657132A2 (en) 2012-04-25 2013-10-30 Airbus Operations GmbH Passenger service system with improved air guidance
WO2013160221A1 (en) 2012-04-25 2013-10-31 Hettich-Oni Gmbh & Co. Kg Sliding door fitting
EP2657329A1 (en) 2012-04-26 2013-10-30 Viking Temizlik Ve Kozmetik Ürünleri Pazarlama Sanayi Ticaret Anomim Sirketi Sequestering agent used in detergents with high calcium binding capacity
EP2661028A1 (en) 2012-04-30 2013-11-06 Fujitsu Limited Duplicate Packet Suppression
WO2013164213A1 (en) 2012-05-04 2013-11-07 Construction Research & Technology Gmbh Process for manufacturing a hydraulic bonding agent, corresponding additive and its use
WO2013171027A1 (en) 2012-05-16 2013-11-21 Unilever N.V. Process for the preparation of edible fat-continuous emulsions
US11350644B2 (en) 2012-05-16 2022-06-07 Upfield Europe B.V. Process for the preparation of edible fat-continuous emulsions
US8438654B1 (en) 2012-09-14 2013-05-07 Rightscale, Inc. Systems and methods for associating a virtual machine with an access control right
EP2792388A1 (en) 2013-04-19 2014-10-22 Scientific RT GmbH Operating method for an irradiation device
EP2796818A1 (en) 2013-04-22 2014-10-29 Shell Internationale Research Maatschappij B.V. Method and apparatus for producing a liquefied hydrocarbon stream
EP2797200A1 (en) 2013-04-22 2014-10-29 Sanofi-Aventis Deutschland GmbH Apparatus with removable battery
EP2796158A1 (en) 2013-04-22 2014-10-29 Sanofi-Aventis Deutschland GmbH Apparatus including light sources
WO2014173434A1 (en) 2013-04-22 2014-10-30 Sanofi-Aventis Deutschland Gmbh Supplemental device for attachment to an injection device
AT520381A1 (en) * 2017-09-13 2019-03-15 Anton Paar Gmbh X-ray device and method for small angle scattering
WO2019186577A1 (en) 2018-03-27 2019-10-03 Council Of Scientific And Industrial Research A non-invasive and remote method to screen cancer
AU2019246661B2 (en) * 2018-03-27 2020-11-26 Council Of Scientific And Industrial Research A non-invasive and remote method to screen cancer
US11561187B2 (en) 2018-03-27 2023-01-24 Council Of Scientific And Industrial Research Non-invasive and remote method to screen cancer

Similar Documents

Publication Publication Date Title
WO2011000020A1 (en) Enhanced method of detection
Sjövall et al. Imaging the distribution of skin lipids and topically applied compounds in human skin using mass spectrometry
EP2440937B1 (en) A diagnostic method
De Carvalho et al. Chemotherapeutic response to cisplatin-like drugs in human breast cancer cells probed by vibrational microspectroscopy
EP2453226B1 (en) X-ray dark-field imaging system and method
Potdevin et al. X-ray vector radiography for bone micro-architecture diagnostics
WO2006016597A1 (en) Method of evaluating physical conditions using head hair or body hair
Huang et al. In-line phase-contrast and grating-based phase-contrast synchrotron imaging study of brain micrometastasis of breast cancer
Whitehead et al. Applying in vitro NMR spectroscopy and 1H NMR metabonomics to breast cancer characterization and detection
Coello et al. Quantitative evaluation of the mineralization level of dental tissues by Raman spectroscopy
US10238291B2 (en) Method for diagnosing dental demineralization processes
Carneiro et al. Impact of the Pd2Spm (Spermine) Complex on the Metabolism of Triple-Negative Breast Cancer Tumors of a Xenograft Mouse Model
Han et al. Analysis of facial sebum distribution using a digital fluorescent imaging system
Keuenhof et al. Multimodality imaging beyond CLEM: Showcases of combined in-vivo preclinical imaging and ex-vivo microscopy to detect murine mural vascular lesions
Holme et al. Morphology of atherosclerotic coronary arteries
EP3724645B1 (en) A non-invasive and remote method to screen cancer
EP3545299B1 (en) In vitro method for detecting active mycobacterium tuberculosis using hair small angle x-ray scattering profile
Wares et al. Noninvasive evaluation of hemodynamics and light scattering property during two-stage mouse cutaneous carcinogenesis based on multispectral diffuse reflectance images at isosbestic wavelengths of hemoglobin
Jang et al. Micro‐and nano‐tomography analysis of mouse soleus muscle using radiation
Ali et al. Detection of human brain tumours via evaluation of their biochemical composition using ATR-FTIR spectroscopy
Kainerstorfer et al. Depth discrimination in diffuse optical transmission imaging by planar scanning off-axis fibers: initial applications to optical mammography
Sunaguchi et al. Three-dimensional reconstruction of human nipple using refraction-contrast x-ray computed tomography
US20220160233A1 (en) Raman computed tomography (raman-ct) system and method
Erickson et al. Fast coregistered breast imaging in vivo using a hand-held optical imager
Ciubuc Raman Computational and Experimental Studies on Label-Free Biological Investigations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09846649

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09846649

Country of ref document: EP

Kind code of ref document: A1